

ONC 7 – Med Chem of Topoisomerase and Microtubule Inhibitors and Crosslinking Agents

Today, we will cover three major anti-cancer drug strategies

1. **Interfering with DNA processing, replication and transcription**
Rationale: Cancer cells replicate their DNA more frequently and must transcribe DNA into mRNA more frequently to keep up with protein production. Blocking DNA unwinding and interfering with transcription will disproportionately affect cancer cells.

2. **Messing with Microtubule dynamics**
Rationale: The formation and break-down of microtubules is critically important during cell division and replication. Because cancer cells undergo replication more frequently than healthy cells, they will be more sensitive to disruptions in microtubule dynamics.

3. **Switching off signaling pathways (Inhibiting Protein kinases)**
Rationale: Cancer cells are self-sufficient in growth signaling – they are constantly switched on, rapidly growing and proliferating. By blocking the signals that tell cancer cells to grow, one can induce cell death and slow the growth and progression of disease. In contrasts, most healthy cells are usually switched off and can survive if a single signaling pathway is blocked.

1. Cancer Cells replicate much *more frequently* therefore any disruption will **disproportionately affect** them

2. Microtubules are important during **cell division and replication** (anaphase, positioning, etc) therefore same disproportionate effect.

3. Many types of cancers have **constitutively active** signal pathways → abnormal growth

Describe the MoA for commonly used Oncology Drugs

Generally, **Alkylation** refers to the *transfer* of an alkane group from one molecule → another molecule. In biology however, this definition is slightly expanded to **covalent modification of DNA** (adding on more than just alkyl groups). Alkylation of DNA physiologically is important for *normal cell function* such as;


- **Methylation** of Cytosine will *impair transcription*
- **Hypermethylation** of Promoter Regions can cause *silencing* of Tumor Suppressor Proteins → Cancer
- **Hypomethylation** of Promoter Regions can cause *overexpression* of Oncogenes → Cancer
 - Methylation in general impairs transcription so some scenarios we will have too much or too little of what we want

Nitrogen Mustards


Earlier cancer therapies that utilized the use of Alkylation to **damage DNA** involved the use of various **mustard gases**.



An important general note about Nitrogen Mustards is that the **intramolecular S_N2 reaction** is *much faster* than the **intermolecular interaction with DNA**. Therefore the reactive, 3-membered ring compound will always form first then alkylate DNA.




When these reactive species alkylate DNA, they tend to create **inter-strand crosslinking** between the two strands in dsDNA.







Older agents were found to be more toxic and displayed little selectivity for tumor cells over healthy cells.

- Newer agents introduced an **Aryl Group** to decrease the nucleophilicity of the nitrogen atom → ↑ t_{1/2} (slower activation step into reactive species)

Cyclophosphamide is an example of a Nitrogen Mustard **Prodrug**;



Enzyme	Notes
Topoisomerase I	Enzyme that will cleave DNA Backbone to relieve pressure and allow for uncoiling/unwinding Will use the energy stored in the strain instead of using ATP or Cofactors Will stay <i>connected</i> to DNA as it unwinds through a covalent bond between a Tyrosine residue and PO_4^- on backbone <u>Topoisomerase I Inhibitors</u> Irinotecan (Prodrug)  → Active component  Typically planar with a lactone ring that is metabolized for <i>inactivation</i> Will bind to the cleavage site that Topoisomerase I has activity at and will mimic base pairing → intercalation to prevent reattachment after cleavage.
Topoisomerase II	Teniposide  Etoposide  Enzyme that will cleave dsDNA to allow another dsDNA strand to pass through - Is a Homo-Dimer (2 units) that will bind with a 4 base stagger using Tyrosine Residues - Will require ATP and Metal Activation for activity <u>Topoisomerase II Inhibitors</u> Based off of an older natural product (Microtubule Inhibitor)

	Will also block the reattachment step preventing reformation
	Since Topoisomerase II is a homo-dimer, will need 2 drug molecules to inhibit

Summary:

Topo I:

- Induces a **single strand break** in the DNA backbone (cleaves the O-P bond)
- Forms a **hinge**, to unwind and allow DNA coil to relax
- Religates (sticks back together) cleaved fragments to form double stranded DNA
- A **single molecule of Topo I** can efficiently execute the single strand break

Topo II:

- Induces a **double strand break** in DNA, allowing a second intact DNA strand to pass through the break and then religates
- **Two molecules of Topo II** are required to induce a double strand break (one to cleave and religate each strand)

Topoisomerase inhibitors **block the religation step** to induce DNA damage response and cell death

Tubulin Inhibitors


The **Mitotic Spindle** is a required apparatus for cell division (anaphase) and therefore cell proliferation.

- **Microtubules** are tubulin polymers that make up the Mitotic Spindle and their synthesis relies on the hydrolysis of **GTP → GDP**
 - o α tubulin is **stable**
 - o β tubulin is **unstable** and is the one that is hydrolyzed
 - o **Microtubule Collapse** occurs when GTP hydrolysis (of β tubulin) has completely reached the (+) end from the (-) end

There are several binding pockets on Tubulin that have been targeted by drugs.

Destabilizers

- 1. **Vinca site**: Vincristine and vinblastine, introduces a wedge causing curved polymers
- 2. **Colchicine site**: Colchicine and Combretastatin*, impair α-β interactions
- 3. **Maytansine site**: Maytansine, Rhizoxin*, blocks polymerization



Stabilizers

- 4. **Taxane site**: Paclitaxel, Docetaxel, impair depolymerization of polymers (stabilize)

Slowing down Microtubule Dynamics → slower cell proliferation and growth (cancer)

Kinase Inhibitors

Tyrosine Kinases are enzymes that transfer phosphate groups from ATP → Tyrosine.

- The ATP binding site is similar across all types of Tyrosine Kinases → difficulty with *selectivity*

To bind to the ATP binding site, Tyrosine Kinase Inhibitors will need to **mimic ATP (specifically Adenosine)**

- Often have a *purine or purine mimetic* that binds that is similar in structure to Adenosine
- Will try to impart *selectivity* by having a portion reach into the **substrate binding pocket** (can tailor to specific substrates)